<DOC>
	<DOCNO>NCT00243568</DOCNO>
	<brief_summary>This international study vicriviroc 500 adult HIV-infected subject fail standard antiretroviral therapy ( ART ) . HIV must certain type know R5/X4-mixed tropic . Subjects allow trial randomly assign treatment vicriviroc 10 mg QD , vicriviroc 15 mg QD , placebo addition antiretrovirals ( select investigator optimal specific subject ) contain least 3 drug , include protease inhibitor ( PI ) boost least 100 mg ritonavir QD . Subjects continue 48 week dose .</brief_summary>
	<brief_title>Vicriviroc , CCR5 Inhibitor , Added Optimized Antiretroviral Therapy Previously Treated HIV ( VICTOR-E2 ) ( Study P04285 ) ( TERMINATED )</brief_title>
	<detailed_description>This randomize , placebo-controlled , multi-site , parallel-group , double-blind study vicriviroc ( SCH 417690 ) 500 adult HIV-infected subject R5/X4 mixed viral tropism least 5000 copies/mL HIV RNA despite standard antiretroviral therapy ( ART ) subject receive continuously least 3 month . Eligible subject randomize treatment vicriviroc 10 mg QD , vicriviroc 15 mg QD , placebo addition individually optimize PI-containing ART regimen contain least 3 drug , include PI , boost least 100 mg ritonavir QD prescribe investigator . The vicriviroc dose placebo double-blind , optimize background therapy open-label . Treatment visit Day 1 schedule Weeks 1 , 2 , 4 , 8 , 12 , 16 , 20 , 24 , 32 , 40 , 48 . A planned interim analysis conduct 100 subject complete 12 week dose . After completion primary analysis ( 24-week virologic response subject ) , subject give optimal dose vicriviroc follow-up continue least 48 week . Safety monitor standard laboratory test , assessment adverse event , emergence complicate medical condition . Cardiac safety monitor periodically ECG , plasma sample collect subject study population pharmacokinetic analysis .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Adult subject document R5/X4 mixedtropic HIV infection Prior therapy great equal 3 month great equal 3 class currently market antiretroviral agent ( NRTIs , NNRTIs , PIs , fusion inhibitor ) time prior screen HIV RNA great equal 5000 copies/mL stable ART regimen least 3 month duration Greater equal 1 genotypically document resistance mutation reverse transcriptase ( RT ) inhibitor great equal 1 primary resistance mutation PI Acceptable hematologic , renal , hepatic laboratory parameter . No history recurrent seizure CNS condition predispose seizure No active AIDSdefining opportunistic infection Subjects previously use CCR5 inhibitor great 4 week and/or within 30 day screen visit Use drug predispose seizure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>CCR5/CXCR4 mix tropism</keyword>
	<keyword>R5/X4 mix tropism</keyword>
	<keyword>CCR5 inhibitor</keyword>
	<keyword>vicriviroc</keyword>
	<keyword>treatment-experienced</keyword>
</DOC>